All In Biotech

Drug Trial Radar · NCT07317544

Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Adult Participants With and Without Androgenetic Alopecia

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 227 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

227

Planned (sponsor's estimate)

Start

Dec 3, 2025

Primary completion

Jul 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Absci Pty Ltd.Industry
Sponsor type
Industry
First posted
Jan 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human study of ABS-201, a new investigational medicine, in healthy adult men and women. Its main purpose is to find out whether ABS-201 is safe and well tolerated, as well as to understand how the body processes it and how it affects related biological markers. ABS-201 is being developed as a possible treatment for androgenetic alopecia (male- and female-pattern hair loss); its effect on hair growth has not yet been established. The study has two parts: in the single ascending dose (SAD) part, healthy adults receive one intravenous dose of ABS-201 or placebo; and in the multiple ascending dose (MAD) part, participants (including men with androgenetic alopecia) receive several subcutaneous doses of ABS-201 or placebo. The MAD part also evaluates the effect of ABS-201 on hair growth. The main questions it aims to answer are: What medical problems, if any, do participants experience when taking a single dose or many doses of ABS-201? How does the medication, ABS-201, compare to placebo (a look alike substance that does not contain any medication). Participants who qualify for the trial will receive either ABS-201 or a placebo, and visit the study clinic for scheduled checkups and tests for approximately 12 months in the single ascending dose (SAD) part and approximately 18 months in the multiple ascending dose (MAD) part. In the MAD part, participants receive repeated subcutaneous doses.

Conditions

  • Androgenetic Alopecia (AGA)
  • Healthy Volunteers - Male and Female

Interventions

  • SAD IV Dose 1 - 150mg ABS201 IV Single DoseDrug

    ABS-201 is an IgG1 monoclonal antibody developed to specifically target the prolactin receptor (PRLR)

  • Placebo IVDrug

    Matching placebo

  • ABS-201 SC Multiple DosesDrug

    Multiple doses of ABS-201 for Subcutaneous injection

  • Placebo SC InjectionDrug

    Subcutaneous Placebo injection for MAD arms

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rate of treatment-emergent adverse events (TEAEs) and serious TEAEsTime frame: From enrollment to the end of the Study (SAD approximately 12 months, MAD approximately 18 months)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Momentum Darlinghurst

    Sydney, New South Wales, Australia · Recruiting

  • Nucleus Network Brisbane

    Brisbane, Queensland, Australia · Recruiting

  • Sinclair Dermatology

    Melbourne, Victoria, Australia · Recruiting

  • Nucleus Network

    Melbourne, Victoria, Australia · Recruiting

  • DermCo Pty Ltd

    South Perth, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.